Sun Pharmaceutical Industries Ltd. reported consolidated FY24 Q4 net revenue grew 34% to ₹2,654 crore from ₹1,984 crore within the 12 months ancient times.
Q4 product sales grew 10.1% at ₹11,813 crore.
The agency’s FY24 consolidated net revenue grew 13% to ₹9,576 crore from ₹8,473 crore. Gross gross sales grew 10.4% to ₹47,758.5 crore.
The Board proposed a last dividend of ₹5 per share for FY24. This is as well as to the interim dividend of ₹8.5 per share paid in FY24, taking the entire to ₹13.5 per share within the final fiscal in contrast with ₹11.5 per share in FY23.
The Board additionally permitted appointment of Dilip Shanghvi, MD of the corporate, because the Chairman of the Board with speedy impact.
Dilip Shanghvi, Chairman and MD stated, “During FY24, two of our businesses surpassed $1 Billion in annual sales, namely Global Specialty and Emerging Markets.”
“This achievement of critical mass in key markets is a testimony to several years of hard work put in by respective teams. We shall continue to build our specialty portfolio and invest further to gain scale across our businesses.”
